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Abstract
Background: Bacillus anthracis is an animal and human pathogen whose virulence is characterized
by lethal and edema toxin, as well as a poly-glutamic acid capsule. In addition to these well
characterized toxins, B. anthracis secretes several proteases and phospholipases, and a newly
described toxin of the cholesterol-dependent cytolysin (CDC) family, Anthrolysin O (ALO).
Results: In the present studies we show that recombinant ALO (rALO) or native ALO, secreted
by viable B. anthracis, is lethal to human primary polymorphonuclear leukocytes (PMNs),
monocytes, monocyte-derived macrophages (MDMs), lymphocytes, THP-1 monocytic human cell
line and ME-180, Detroit 562, and A549 epithelial cells by trypan blue exclusion or lactate
dehydrogenase (LDH) release viability assays. ALO cytotoxicity is dose and time dependent and
susceptibility to ALO-mediated lysis differs between cell types. In addition, the viability of
monocytes and hMDMs was assayed in the presence of vegetative Sterne strains 7702 (ALO+),
UT231 (ALO-), and a complemented strain expressing ALO, UT231 (pUTE544), and was
dependent upon the expression of ALO. Cytotoxicity of rALO is seen as low as 0.070 nM in the
absence of serum. All direct cytotoxic activity is inhibited by the addition of cholesterol or serum
concentration as low as 10%.
Conclusion:  The lethality of rALO and native ALO on human monocytes, neutrophils,
macrophages and lymphocytes supports the idea that ALO may represent a previously unidentified
virulence factor of B. anthracis. The study of other factors produced by B. anthracis, along with the
major anthrax toxins, will lead to a better understanding of this bacterium's pathogenesis, as well
as provide information for the development of antitoxin vaccines for treating and preventing
anthrax.
Background
Bacillus anthracis, a spore-forming, aerobic, Gram-positive
bacterium is the causative agent of the disease anthrax.
The fact that the B. anthracis spores are highly lethal, inex-
pensively made, easily produced and disseminated as
weapons of terror, necessitates the need for a better under-
standing of the pathogenic mechanisms and virulence fac-
tors of this organism using human cells [1-3]. In all forms
of anthrax, gastrointestinal, pulmonary, or cutaneous, B.
anthracis spores are phagocytosed by residing intestinal,
alveolar, or skin macrophages where they germinate into
vegetative bacilli. The macrophages then travel to the
lymph nodes where the vegetative B. anthracis must escape
the macrophage's vacuole into the cytoplasm and eventu-
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ally the macrophage itself. Bacilli multiply in the lymphat-
ics and enter the bloodstream, where they can reach
numbers of 107 to 108 per milliliter [1].
Bacillus anthracis vegetative bacteria express virulence fac-
tors that are encoded by two virulence plasmids, pXO1
and pXO2 [1,4,5]. pXO1, the toxin gene-bearing, regula-
tory plasmid, encodes the known components of B.
anthracis exotoxins: lethal factor (LF), edema factor (EF)
and protective antigen (PA). Together with pXO2, the cap-
sule producing plasmid, anthrax toxins are thought to be
responsible for the high morbidity and pathology of
anthrax during the late stage of disease and have been a
primary focus of B. anthracis research for decades.
Although anthrax lethal toxin (LT) may contribute signif-
icantly to septicemia and death of the host, other viru-
lence factors may be important in establishing infection
and may contribute to disease [2,6,7].
In vitro and  in vivo, vegetative B. anthracis express and
secrete a protein which is member of the cholesterol-
dependent cytolysin (CDCs) family of cytolysins. The pro-
tein, which we have named Anthrolysin O (ALO), acts as
a hemolysin against human red blood cells and is differ-
entially regulated by environmental signals [8-10]. Mem-
bers of the CDC family of cytolysins are secreted and bind
cholesterol and other molecules in the host cell plasma
membrane forming large pores which range in diameter
from 20 to 30 nm [11-13]. The formation of pores in cho-
lesterol-containing membranes confers this family of
toxin's hemolytic and cytolytic properties. CDCs are inti-
mately involved in the pathogenesis of more than 20
Gram-positive species including Arcanobacterium pyogenes,
Clostridium perfringens, Bacillus cereus, Listeria monocy-
togenes, Streptococcus pyogenes and Streptococcus pneumoniae
[14-18]. At high concentrations, CDCs function as cyto-
toxins, lysing host immune cells; Perfringolysin O, PFO, is
cytolytic to macrophages; Pneumolysin, PLY, lyses murine
macrophages and bovine PMNs, and; SLO of S. pyrogenes
lyses human PMNs [19-22]. Many of these pathogens
secrete CDCs in sub-lytic amounts that function to mod-
ulate phagocytic cell function by inhibiting chemotaxis,
the oxidative burst, or phagocytosis, and activate comple-
ment [12,15,23-27]. Most recently CDCs, including ALO,
have been described as TLR4 agonists [28-30].
During B. anthracis infection the events associated with
phagocyte membrane disruption, phagocyte death, and
escape of vegetative bacilli from the phagocyte have yet to
be fully elucidated. This prompted us to examine the role
that ALO might play as a cytolysin against human phago-
cytes. We hypothesize that ALO can be defined as a new B.
anthracis  virulence factor, which has the ability to lyse
human monocytes, human monocyte-derived macro-
phages (hMDMs), lymphocytes and neutrophils (PMNs).
Our studies reveal by trypan blue exclusion assay and by
the release of LDH, that purified recombinant ALO
(rALO) is cytolytic to THP-1 monocytes, freshly isolated
PMNs, lymphocytes, hMDMs, ME-180, Detroit 562, and
A549 epithelial cells. Furthermore, using Sterne strain
7702, an ALO-negative mutant, and a complemented
strain expressing the native alo gene, we show that viable,
vegetative B. anthracis, or their supernatants, lyse THP-1 s
and macrophages in a dose dependent manner. We dem-
onstrate that the death of the leukocytes is dependent
upon ALO.
Results
Recombinant ALO lyses human primary phagocytes and 
lymphocytes in a dose and time dependent manner
Overnight growth supernatants from Sterne strain 7702
and rALO are hemolytic to human [8] and mouse red
blood cells (data unpublished). However, we did not
know if ALO was cytolytic to human leukocytes. Because
of the lethal effects of other CDCs on human and mouse
phagocytes, we hypothesized that ALO would act simi-
larly, lysing human phagocytes and lymphocytes [19-22].
We assayed for the ability of purified rALO to lyse freshly
isolated human neutrophils by incubating neutrophils
under serum-free conditions with a range of rALO concen-
trations. Addition of trypan blue to the cells and subse-
quent blind counting of at least 100 cells, show that as
little as 4 ng/ml of rALO, which is approximately 0.070
nM, lysed neutrophils (Fig. 1). Lysis of the cells occurred
within 30 min and little difference was seen at later time
points. Addition of heat-inactivated 10% FBS before the
addition of rALO inhibited lysis at all concentrations
Recombinant ALO lyses primary human neutrophils in a dose  dependent manner Figure 1
Recombinant ALO lyses primary human neutrophils 
in a dose dependent manner. Percent viability of PMNs 
measured by trypan blue after 10 min incubation with various 
concentrations of rALO in serum free conditions. The means 
and standard deviations of two independent experiments, 
each performed in duplicate are shown (Spearman correla-
tion is -0.842, p = 0.004).
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tested. Likewise, when 1 μg/ml of free cholesterol was pre-
incubated with rALO before addition to the PMNs, viabil-
ity of the PMNs remained the same as controls (data not
shown).
To determine if human monocytes and macrophages were
as susceptible to rALO mediated lysis as human neu-
trophils, we assayed the death of the human monocyte
line THP-1 and hMDMs after incubation with rALO. Via-
bility was measured by trypan blue exclusion and verified
using an LDH based cytotoxicity assay. In the absence of
serum 17.5 ng/ml, or 0.30 nM, of rALO caused 50 % lysis
of THP-1s. These results indicate that PMNs are 5 times
more sensitive to ALO mediated lysis than are THP-1s
(Fig. 2).
Macrophages are thought to be the primary cells in/on
which B. anthracis spores germinate, thus we sought to
determine the cytolytic effect of rALO on primary hMDMs
that had been differentiated for 5 days with M-CSF. After
incubation for 30 min with rALO, in the absence of
serum, the viability of hMDMs was assayed by trypan blue
dye exclusion. In dose-response experiments, rALO was
cytolytic to hMDMs (Fig. 3). As seen with human neu-
trophils and THP-1 monocytes, hMDMs are differentially
lysed by rALO, requiring approximately 100 ng/ml, or 1.8
nM rALO to cause 50 % lysis.
Lymphocytes, although not cells of focus in B. anthracis
infection, were also tested for their susceptibility to rALO
lysis after observing different degrees of cell cytotoxicity
depending upon the cell type assayed. Much like THP-1s,
total lymphocytes isolated from human blood were lysed
by rALO in a dose dependent manner in both the absence
and, significantly to a lesser extent, in the presence of heat-
inactivated 10% FBS (p = 0.001, student's un-paired t-test)
(Fig. 4). Approximately 25 ng/ml, or 0.44 nM, of rALO
was needed to cause 50 % lysis of human lymphocytes.
After establishing rALO's ability to lyse phagocytes and
lymphocytes and observing their varying susceptibility to
rALO-mediated lysis, we were prompted to investigate
rALO's ability to lyse epithelial cells. Cells of the epithelial
cell line ME-180 and Detroit 562 were incubated with var-
ying concentrations of recombinant ALO for 30 min. The
plate was briefly centrifuged and the supernatants used to
determine percent viability using LDH release. Surpris-
ingly, our results show that a much greater rALO concen-
tration, almost 1 μg/ml, is required to cause 50 % lysis of
ME-180 cells and Detroit 562 cells in the absence of serum
(data not shown). There was no decrease in ME-180 epi-
thelial cell viability even after a 3 h incubation. Similar
results were observed using trypan blue exclusion. In con-
trast, when A549 lung epithelial cells were assayed for via-
bility, approximately 50 ng/ml, or 0.88 nM of rALO was
needed to cause 50% lysis (data not shown).
Recombinant ALO lyses human monocytic THP-1 cells in a  dose-dependent manner Figure 2
Recombinant ALO lyses human monocytic THP-1 
cells in a dose-dependent manner. Percent viability of 
THP-1 monocytes measured by trypan blue after 30 min 
incubation with various concentrations of rALO in serum 
free conditions. Results show that 50% of THP-1s are lysed 
by 0.35 nM of rALO. The means and standard deviations of 
at least three independent experiments, each performed in 
duplicate, are shown (Spearman correlation is -0.870, p = 
0.002).
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Recombinant ALO lyses human monocyte derived macro- phages (hMDMs) in a dose dependent manner Figure 3
Recombinant ALO lyses human monocyte derived 
macrophages (hMDMs) in a dose dependent manner. 
Percent viability of primary human monocyte derived macro-
phages after 30 min incubation at 37°C with varying concen-
trations of rALO in serum free conditions. The means and 
standard deviations of three independent experiments per-
formed in duplicate are shown. Each experiment was per-
formed with hMDMs from different donors (represented by 
▲, , ■) (▲, Spearman correlation is -0.917, p = 0.001. , 
Spearman correlation is -0.962, p < 0.001. ■, Spearman cor-
relation is -0.852, p = 0.015).
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Native ALO lyses human monocytes and macrophages
To determine the role of ALO in B. anthracis-mediated
cytotoxicity we investigated the ability of B. anthracis
growth supernatants to lyse hMDMs. We asked the ques-
tion whether native, secreted ALO lysed phagocytes in a
similar manner to rALO. We have quantified the amount
of ALO present in the supernatant of the ALO-overproduc-
ing strain, UT231 (pUTE544), by ELISA and hemolysis
assays using a standard curve of rALO (n = 3, data not
shown). Supernatant of UT231 (pUTE544) grown in BHI
contains 1.38 ± 0.12 μg/ml ALO. Hemolysis assays
revealed that the parent strain, 7702, grown under the
same conditions, produces approximately 1,000-fold less
ALO. Hemolysis is abrogated by the addition of 1 μg/ml
of free cholesterol, indicating that the hemolysis is caused
by ALO [8] (Fig. 5). Using this knowledge, late exponen-
tial phase cell free supernatants from the wild-type strain,
7702, were compared to supernatants obtained from the
ALO knockout strain, UT231, and the complemented
overproducing strain, UT231 (pUTE544), in their ability
to lyse hMDMs. We hypothesized that strains producing
ALO would be more cytolytic to hMDMs than the ALO
knockout strain. Supernatants of strains 7702 and UT231
(pUTE544) caused significantly greater amounts of cytol-
ysis of hMDMs than the ALO knockout strain UT231 (Fig.
6). Some cytolytic variability is seen from blood donor to
blood donor, however overall lytic death occurs in a dose
and strain, i.e. ALO dependent manner (p < 0.001, 2-way
ANOVA, p < 0.001, Tukey test). Thus, native ALO, in addi-
tion to rALO, lyses human macrophages.
Bacillus anthracis secreting ALO lyses human monocytes 
and macrophages
Similarly, to determine if ALO played a role in the ability
of live B. anthracis to lyse phagocytes, B. anthracis strains
7702, UT231 (ALO-), and UT231 (pUTE544) (ALO++)
were grown to late log phase in BHI, washed and incu-
bated with cells of the human monocytic cell line THP-1.
Our results show that only bacteria expressing ALO com-
pletely lyse THP-1s in the absence of serum. Statistical
analyses at a MOI of 100 at the 30 min, 1 h and 2 h time-
points show that 7702 and UT231 (pUTE544) lyse signif-
icantly more THP-1s than the ALO knock-out, UT231 (p <
0.001, 1-way ANOVA and p < 0.001, Tukey test (Fig. 7).
Similar significance was also observed at a MOI of 10 after
1 h and 2 h. The decrease in viability by UT231 (ALO-) at
an MOI of 1000, and to a lesser extent at MOI of 100, was
noted, perhaps due to the effects of the major anthrax tox-
ins or unknown toxins. However, an ALO-dependent dose
and time response was observed when THP-1 cells were
incubated with the ALO over-producing strain and 7702
over the 2 h time course examined. Therefore, addition of
whole bacteria secreting ALO reproduced the observed
cytolytic effects seen with purified recombinant protein.
Addition of cholesterol abrogates ALO cytotoxicity of 
human monocytes
The presence of free cholesterol inhibits ALO-mediated
lysis [8]. To support our hypothesis that ALO causes the
observed cytolysis of THP-1 monocytes, cholesterol inhi-
bition studies were performed. At an MOI of 1000 bacte-
ria:monocyte the lysis caused by B. anthracis 7702 (ALO+)
and the complemented strain expressing ALO, UT231
(pUTE544) (ALO++) at 5 min was completely inhibited
by pre-incubation of monocytes with heat-inactivated
10% FBS (Table 2). Similar results were seen using 1 μg/
ml cholesterol (data not shown). After 1 h incubation
insufficient amounts of cholesterol were present to inhibit
the lysis caused by UT231 (pUTE544). These results are
consistent with the inhibition of ALO's hemolytic activity
by 1 μg/ml cholesterol in hemolysis assays and show that
the observed B. anthracis cytotoxicity is a direct result of
native ALO (Fig. 5).
Discussion
In vitro, under nutrient rich growth conditions, and in vivo
B. anthracis expresses and secretes a protein that is a mem-
ber of the CDC family of cytolysins, which we have
named ALO [8,9]. CDCs are closely involved in the patho-
genesis of several Gram-positive bacteria, acting both lyti-
cally to lyse cells as well as sub-lytically, modulating the
immune response and basic immune cell function [14-
19,23-26,29,31]. CDCs, including ALO, stimulate
Recombinant ALO lyses primary human lymphocytes in a  dose dependent manner Figure 4
Recombinant ALO lyses primary human lym-
phocytes in a dose dependent manner. Percent viability 
of lymphocytes measured with trypan blue after 30 min incu-
bation with varying concentrations of rALO at 37°C with no 
serum or heat-inactivated 10%. The means and standard 
deviations of at least three independent experiments, each 
done in duplicate, are shown (Spearman correlation is -0.964, 
p < 0.001). Addition of 10% serum significantly inhibits ALO-
mediated lymphocyte lysis (*p = 0.001 as calculated by stu-
dent's unpaired t-test).
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through TLR4. Interestingly, ALO in conjunction with LT,
at sub-lytic concentrations, is responsible for inducing
apoptosis of macrophages. Furthermore, as a TLR4 ago-
nist, ALO has the ability to induce an inflammatory
response [29]. During the course of B. anthracis infection,
the local concentration or expression of ALO likely varies,
thus we hypothesized that ALO may act similarly to other
CDCs and lyse human phagocytes, lymphocytes and epi-
thelial cells. The secretion of a CDC by B. anthracis under
certain growth conditions and the ability of this CDC to
lyse human leukocytes may have implications regarding
our understanding of basic B. anthracis pathogenesis.
Our results demonstrate that ALO causes cytolysis of pri-
mary human macrophages, neutrophils, lymphocytes and
cells of the THP-1 human monocyte cell line in a dose and
time dependent manner. Purified rALO, native ALO and
B. anthracis expressing ALO all lyse human leukocytes. The
observed cytotoxicity correlates with the proposed mode
of action of ALO, namely, a multiunit accumulation of
ALO molecules within the membrane of cells resulting in
pore formation. Leukocyte and lymphocyte lysis by ALO
occurred within 30 min, which is indicative of necrotic
death. Likewise, when rALO-treated cells were assayed for
apoptotic death by ethidium bromide/acridine orange
staining, necrosis, but no apoptosis was evident (data not
shown).
ALO cytotoxicity varied significantly in the different
human cell types tested. PMNs were the most sensitive to
ALO mediated lysis with 50 % lysis occurring at just 0.070
nM ALO. THP-1 monocytes, lymphocytes and monocyte-
derived macrophages were 5.0, 6.25 and 25.0 times more
resistant to ALO than were PMNs, respectively. Remarka-
bly, in similar conditions, ME-180 and Detroit 562 epi-
thelial cells were 250 times more resistant to ALO-
mediated lysis than PMNs (Table 1). These differences in
sensitivities between cell types are presently under study.
Like rALO, ALO-producing B. anthracis strains were cyto-
lytic for human phagocytes. Cytotoxicity was abrogated
by addition of cholesterol, confirming that lysis by B.
anthracis is ALO-dependent under the conditions tested.
Cholesterol is required for the binding of CDCs to cell
membranes, and addition of free cholesterol acts as a
competitive inhibitor for CDC binding and pore forma-
tion [32]. It is important to note, however, that intermedi-
lysin does not use cholesterol as its receptor. Instead,
glycosyl-phosphatidylinositol-linked membrane protein
human CD59 is required for pore formation [11]. In cyto-
toxicity assays in which Sterne strain 7702, the over-
expressing UT231 (pUTE544), or the ALO- strain UT231
were incubated with THP-1 monocytes, only bacteria pro-
ducing ALO caused a dose and time dependent lysis of the
cells (Fig. 7).
Hemolytic activity of BHI growth supernatants of B. anthracis strains 7702, the parent ALO+ strain, and UT231(pUTE544), the  ALO knockout strain complemented in trans with a plasmid bearing the alo gene Figure 5
Hemolytic activity of BHI growth supernatants of B. anthracis strains 7702, the parent ALO+ strain, and 
UT231(pUTE544), the ALO knockout strain complemented in trans with a plasmid bearing the alo gene. 
UT231 (pUTE544) produces about 1,000-fold more ALO. Hemolytic activity is reduced upon the addition of 1 μg/ml choles-
terol. Results are representative of at least three independent experiments done in duplicate.BMC Microbiology 2006, 6:56 http://www.biomedcentral.com/1471-2180/6/56
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We have previously shown that during late exponential
phase maximal amounts of ALO are secreted by B. anthra-
cis, thus we assessed hMDM lysis by native ALO using bac-
terial growth supernatants[8]. When hMDMs were
incubated with cell free late exponential phase growth
supernatants from the parent strain 7702, a defined ALO
knockout UT231, or the over-expressing ALO strain
UT231 (pUTE544), significantly less cytotoxicity was
observed with UT231 supernatants compared to superna-
tants of the parent and overproducing strains, indicating
that ALO is the major factor contributing to the cytotoxic-
ity of these phagocytes (p < 0.001, 2-way ANOVA and p <
0.001, Tukey test) (Fig. 6). These results strongly indicate
that ALO is responsible alone or in conjunction with
other toxins for the observed lysis. The death observed
when UT231 (ALO-), supernatants were incubated with
the hMDMs may be attributed to the major toxins, LT and
ET. Overall, these data support our hypothesis that ALO at
lethal concentrations may be involved with anthrax
pathogenesis by lysing human neutrophils and mono-
cytes/macrophages or by rendering them non-functional.
The mechanism responsible for the differential suscepti-
bility of the human phagocytes and epithelial cells to ALO
is largely unaccounted for and remains an interest of our
lab. In cholesterol depletion experiments, lysis of THP-1s
and mouse macrophages RAW 264.7 cells is abrogated
Bacillus anthracis strains secreting ALO lyse THP-1 mono- cytes in a dose and time dependent manner Figure 7
Bacillus anthracis strains secreting ALO lyse THP-1 
monocytes in a dose and time dependent manner. 
Percent viable THP-1 s in the presence of B. anthracis Sterne 
strain (A.)7702 (ALO+), (B.) UT231 (ALO-) and (C.) the 
complemented over-producer, UT231 (pUTE544) (ALO++) 
at MOIs of 1000, 100, 10 and 1 in serum free conditions. At 
time points, aliquots were mixed with 0.25 % trypan blue. 
Results are average ± standard deviations of three experi-
ments, each performed in duplicate. (MOI of 100, 30 min, 1 
h, 2 h, p < 0.001,1 way ANOVA. p < 0.001 for UT231/7702, 
UT231/UT231 (pUTE544), 7702/UT231 (pUTE544), Tukey 
test. MOI of 10, 30 min, 1 h, 2 h, p < 0.001,1 way ANOVA. 
30 min, p < 0.001 for UT231/UT231 (pUTE544) and 7702/
UT231 (pUTE544), Tukey test. 1 h and 2 h, p < 0.001 for 
UT231/7702, UT231/UT231 (pUTE544), 7702/UT231 
(pUTE544), Tukey test.
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Cell free supernatants from B. anthracis secreting ALO lyse  human monocyte derived macrophages significantly more  than the ALO knockout strain, UT231, in a dose dependent  manner Figure 6
Cell free supernatants from B. anthracis secreting 
ALO lyse human monocyte derived macrophages 
significantly more than the ALO knockout strain, 
UT231, in a dose dependent manner. Percent viability 
of hMDMs from three different donors measured by trypan 
blue after the addition of filter sterilized B. anthracis superna-
tants in presence of heat-inactivated 10% FBS. The 3 h time 
point is shown, as little lysis was observed at earlier time 
points. Results are representative of results from three dif-
ferent experiments. (Dose, p < 0.001, strain, p < 0.001, dose 
by strain interaction, p = 0.044, as calculated by 2-way 
ANOVA. Tukey test showing significant differences between 
UT231/7702, UT231/UT231(pUTE544), 7702/
UT231(pUTE544), p < 0.001)
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after the addition of methyl-β-cyclodextrin, suggesting
that in these cell types cholesterol is an important receptor
for the pore forming toxin (in press) [33]. It may be
hypothesized that a difference in membrane cholesterol
composition exists among the cell types tested. Strep-
tolysin O and pneumolysin and have shown different sen-
sitivities to macrophages, monocytes and epithelial cells,
respectively. These differences have been hypothesized to
be the result of basic membrane composition and lipid
raft content, however there are many factors that could
contribute to differences in cell sensitivity [22,34]. ME-
180 and Detroit 562 epithelial cells may be resistant to
lysis even in the absence of free cholesterol due to carbo-
hydrate moieties in the cell membrane that could impede
pore formation. On the other hand, perhaps there is an
unidentified protein receptor necessary for pore forma-
tion in these cells. We also observed differences between
Detroit 562 and A549 epithelial cells, which reside in the
pharynx and lung, respectively. These epithelial cells rep-
resent those that B. anthracis would likely come in contact
with during inhalational anthrax. The observed differ-
ences in cell sensitivity are currently under study. Impor-
tantly, ALO has recently been identified as one of the
hemolytic virulence factors secreted by B. anthracis that is
responsible for increasing shedding of Synd1 and E-cad-
herin from epithelial cells, compromising the epithelial
barrier integrity and perhaps leading to dissemination of
infection [10].
Differential cell susceptibility may have implications
regarding ALO's importance in B. anthracis pathogenesis.
Perhaps PMNs, which are cells known to be first respond-
ers during bacterial infections, are quickly eliminated by
ALO secreted by B. anthracis. Conversely, ALO may be less
cytolytic to macrophages, a primary cell of B. anthracis
pathogenesis, allowing spores to germinate and B. anthra-
cis to persist for a greater length of time inside macro-
phages. Although we do not know the amount of ALO
expressed by B. anthracis within macrophages or when
growing in human blood, Klichko, et al. have noted that
ALO is expressed at the early stages of infection within
mouse macrophages by vegetative bacilli after spore ger-
mination [9]. Additionally, ALO mRNA has been detected
in the spleens of B. anthracis infected mice, indicating that
the gene is expressed in vivo (personal communication, T.
Koehler). Furthermore, antibodies against ALO have been
found in mice infected with Sterne strain B. anthracis
spores, indicating that ALO is produced in vivo in concen-
trations high enough to elicit an immune response [10].
The cytotoxic role of ALO in anthrax pathogenesis, if any,
has thus far not been elucidated. However, this study has
shown that ALO, like its CDC counterparts, is able to lyse
phagocytes. In murine models of pulmonary anthrax, dis-
seminated anthrax results in pathological lesions in the
spleen, ranging from mild to severe necrotizing splenitis.
Lung associated lymph nodes also undergo complete
Table 2: ALO-mediated lysis of human monocytes by B. anthracis is inhibited by 10% FBS. Percent viable THP-1s in the presence of B. 
anthracis Sterne strain 7702 (ALO+), UT231 (ALO-) and the complemented over-producer, UT231 (pUTE544) (ALO++) at an MOI of 
1000 in the presence of 10 % FBS. At various time points, aliquots were mixed with 0.25 % trypan blue to measure viability. Native 
ALO expressed by 7702, at all time points, and UT231 (pUTE544), at 5 min, is inhibited by cholesterol present in heat-inactivated 10% 
FBS. Results are average ± standard deviations of two experiments.
% Viable THP-1 monocytes in presence of 10% FBS
Sterne 7702 UT231 UT231(pUTE544) Control (no bacteria)
5 min 100 100 100 100
30 min 100 100 0 99 ± 0
60 min 95 ± 1 98 ± 2 0 99 ± 0
120 min 92 ± 3.2 96 ± 1 0 97 ± 1
Table 1: Recombinant ALO ED50 in the absence of serum. Results show amount of rALO necessary for 50% cytolysis of primary human 
PMNs, lymphocytes, monocyte-derived macrophages, THP-1 monocytes, ME-180, D562, and A549 epithelial cells after 30 min at 37°C. 
* PMN cytolysis was measured at 10 min. Data derived from Figures 1–5 by cytotoxicity curve extrapolation.
rALO ED50
ng/ml nM
PMNs* 4 0.070
THP-1 monocytes 20 0.35
Lymphocytes 25 0.44
MDMs 100 1.8
ME-180 1000 18
D562 1000 18
A549 50 0.88BMC Microbiology 2006, 6:56 http://www.biomedcentral.com/1471-2180/6/56
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cytolysis [35]. Whether this cytolysis is caused by LT, or
other toxins, remains to be delineated. ALO most likely
acts locally, rather than systemically, affecting PMN
recruitment, macrophage function, or it may confer bacte-
ria an advantage while in or near phagocytes. We have
shown that fewer than 100 molecules of rALO are
required to cause 100% lysis of human erythrocytes [8].
This suggests that B. anthracis would not have to secrete
much ALO within the phagocytic vacuole, within the mac-
rophage cytoplasm, or locally in order to initiate a biolog-
ical response or death of the phagocyte [36]. ALO may be
important in the B. anthracis macrophage interface
whether it be from without or from within macrophages
either before or after phagocytosis of the bacilli occur.
Dixon, et al. suggested that escape from the macrophage
is pXO1 independent and that a gene in the chromosomal
DMA may serve to allow the escape from the macrophage
[6]. Furthermore, lysis of host cells by CDCs helps bacteria
avoid the bactericidal activity of phagocytic cells and aids
in evasion of the host immune response.
Conclusion
The function of ALO's ability to lyse human phagocytes in
B. anthracis pathogenesis is unclear, but this CDC may
contribute to the bacteria's ability to establish, spread, or
cause disease along with the other more characterized tox-
ins. This study further supports ALO as an important viru-
lence factor of B. anthracis. Not only can it act at sub-lethal
concentrations with LT to induce apoptosis, but this study
demonstrates that alone, at higher concentrations, ALO
causes cytolysis of human phagocytes and epithelial cells.
The study of other factors produced by B. anthracis, along
with the major anthrax toxins, will lead to a better under-
standing of this bacterium's pathogenesis as well as pro-
vide more information for the development of anti-toxin
vaccines for treating and preventing anthrax [29].
Methods
Growth of bacterial strains
B. anthracis Sterne strain 7702, a capsule-negative toxi-
genic (containing plasmid pXO1 but not pXO2) strain[5],
was grown in Brain-Heart Infusion broth (BHI; Difco,
Detroit, M.I.), without added bicarbonate, with shaking
(200 rpm) at 37°C in an air shaker incubator (New Bruns-
wick Scientific, Edison N.J.) or on BHI agar in a humidi-
fied 5% CO2 incubator [37]. The bacterial strains UT231,
an ALO knockout, and UT231 (pUTE544), an ALO-over-
expressing, alo complemented strain, used in this study
have been previously described [8]. Growth of UT231 and
UT231 (pUTE544) was supplemented with 50 μg/ml kan-
amycin and 10 μg/ml tetracycline, respectively. Bacteria
were grown to late exponential phase (0.66 absorbance at
600 nm) and washed in PBS before addition to cell cul-
ture. Cell free supernatants were obtained after centrifuga-
tion of cultures at 10,000 rpm for 6 min and subsequent
filtration through 0.22 μm MillexGP filter units (Milli-
pore, Molsheim, France).
Cell culture
The human monocytic cell line THP-1 (ATCC TIB-202)
was maintained in RPMI with heat-inactivated 10% fetal
bovine serum, FBS, (Gibco BRL), and 50 μM beta-mercap-
toethanol at 37°C with 5% CO2 according to ATCC rec-
ommendation. Cells were used between passages 10–20.
The human cervical epithelial-like cell line ME-180
(ATCC HTB-33) was maintained in McCoy's medium
with heat-inactivated10% FBS according to ATCC recom-
mendations. A549 (ATCC CCL-185), human lung epithe-
lial cells, and Detroit 562 (D562, ATCC CCL-138),
human pharyngeal epithelial cells, were maintained
according to ATCC recommendation. All FBS was heat-
inactivated for 30 min at 56°C.
Primary cell isolation
PMNs were isolated from 50 ml of human blood through
Ficoll-Hypaque gradient as previously described [38].
Cells were resuspended to 2 × 106/ml in PBS containing 1
mg/ml gelatin (PBSG) plus 1 mM Ca2+ and 1 mM Mg2+.
Viability and purity were ≥ 95% as determined by trypan
blue staining and basic cell morphology (tri-lobed
nuclei), respectively.
Monocytes were isolated from total mononuclear cells
from 100 ml of human buffy coat (Biological Specialty
Corporation, Colmar, PA) using Ficoll-Paque Plus (Amer-
sham Biosciences, Uppsala, Sweden) followed by enrich-
ment of monocytes using RosetteSep Human Monocyte
Enrichment Cocktail (Stem-Cell Technologies, Vancou-
ver, BC) according to manufacturer directions. To obtain
human monocyte derived macrophages (hMDMs),
monocytes were resuspended in RPMI complete medium
supplemented with 100 μg/ml penicillin/streptomycin
(BioWhittaker, Walkersville, M.D.) and 10 ng/ml recom-
binant human M-CSF (Peprotech, Rock Hill, N.J.). Mono-
cytes were seeded in 24 well cell culture treated plates (Cat
no. 3524, Corning, N.Y.) containing Thermanox cover-
slips (Nalge Nunc, Rochester, N.Y.) at 8 × 104 cells/well
and incubated at 37°C with 5% CO2 overnight. Wells
were washed and replaced with fresh RPMI complete
medium and grown for 5 days until assayed [39]. hMDMs
were washed once with fresh medium before assaying via-
bility. Viability was determined by trypan blue staining to
be ≥ 95%. Cells were more than 95% macrophages as
assessed by adherence to coverslips and non-specific este-
rase staining (α-naphthyl acetate esterase kit, Sigma) fol-
lowing the manufacturer's instructions. The differentiated
phenotype was confirmed by flow cytometry analysis of
CD71 and CD1a (BD Pharmingen, San Diego, CA) at the
cell surface [40].BMC Microbiology 2006, 6:56 http://www.biomedcentral.com/1471-2180/6/56
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Enrichment of total lymphocytes was likewise conducted
using RosetteSep Total Lymphocyte Enrichment Cocktail
(Stem-cell Technologies, Vancouver, BC). Purity and via-
bility were ≥ 95% as determined by trypan blue staining
and expression of CD3 (BD Pharmingen, San Diego, CA)
by flow cytometry analysis, respectively.
Expression and purification of rALO
Recombinant ALO was expressed as described [8]. For use
in assays rALO was diluted in phosphate-buffered saline
(PBS) containing 0.1 mg/ml BSA. 1 mg/ml of cholesterol
(Sigma-Aldrich) stock solution in 100% ethanol was used
in cholesterol inhibition experiments at a final concentra-
tion of 1 μg/ml. Final ethanol concentration is 0.1%. In
cholesterol inhibition experiments an ethanol control was
used, without cholesterol, and did not affect cell lysis.
Hemolysis assay
The assay was performed in 96-well plates. One micro liter
of freshly prepared 0.6 M cysteine in PBS was added to
100 μl of 2-fold (or 10-fold) dilutions of freshly prepared
bacterial supernatants and allowed to incubate at room
temperature for 10 min in a 96-well round-bottom plate.
After incubation, 35 μl of PBS and 15 μl of a 10% (v/v)
suspension of human red blood cells washed four times
with PBS were added to each well. The plate was allowed
to incubate at 37°C for 1 hwith gentle and occasional
rocking and then centrifuged at 700 rpm for 1 min. The
results were read by placing the plate on a horizontal light
box and then viewing (and photographing) the plate from
above.
Measurement of cell viability
PMNs and rALO (diluted accordingly in 0.1% BSA/PBS)
were combined 1:1 in a 1.5 ml eppendorf tube and incu-
bated with gentle tumbling, 15 rpm, at 37°C for 10 min.
10 μl of sample was then added to 10 μl of 0.25% trypan
blue (ICN Biomedicals, Aurora, OH) in 0.85% NaCI. Fol-
lowing 5 min incubation at room temperature the per-
centage of viable cells was calculated by blind counting of
at least 100 cells under 200× to 400× magnification. Via-
ble cells remain colorless whereas dead cells are blue.
THP-1s were cultured in RPMI+10% FBS, washed, and
resuspended in PBS to 2 × 106/ml. THP-1s and rALO
(diluted accordingly in 0.1% BSA/PBS) were combined
1:1 in 1.5 ml eppendorf tubes and incubated with gentle
tumbling at 37°C for 10 min. Lymphocyte viability was
determined as described for the THP-1 s. Monocyte-
derived macrophages were washed once with fresh
medium before assaying viability as described. Reduction
of a tetrazolium dye was measured using the In vitro Tox-
icology based lactate dehydrogenase kit (Sigma-Aldrich
Tox-7) according to manufacturer instructions. The per-
centage of cytotoxicity was calculated as [(sample OD490 -
OD0%)/(OD100% - OD0%)] × 100, where OD0% represents
the OD490 of cells alone and OD100% represents the OD490
of lysed cells. Percent viability was calculated by subtract-
ing percent cytotoxicity from 100. The validity of the LDH
assay was confirmed by comparison with results obtained
from the trypan blue exclusion assay.
Statistical analyses
A p-value that was < 0.05 was considered statistically sig-
nificant. The affect on increasing dose of ALO on cell cyto-
toxicity was evaluated for statistical significance using
Spearman's correlations. Individual samples at each con-
centration served as the unit of analysis. The difference in
the ability of ALO to lyse lymphocytes in the presence or
absence of serum was analyzed for significance by using
student's un-paired t-test (two-tailed p-value). Differences
in viability due to strain (7702, UT231, UT231
(pUTE544) and dose were analyzed for significance using
2 factor analysis of variance (ANOVA). Differences in via-
bility due to strain (7702, UT231, UT231 (pUTE544) were
analyzed for significance using 1 factor analysis of vari-
ance (ANOVA). We chose to analyze MOI of 100 and MOI
of 10, as there is the greatest ambiguity of differences in
viability between strains at these MOIs. 1 and 2 way ANO-
VAs were followed up with Tukey tests to show differences
between each strain. rALO ED50s calculated based upon
dose-response curve extrapolation. The SPSS v. 14 soft-
ware (SPSS, Chicago, IL) was used for these analyses.
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